Skip to main content
Erschienen in: Digestive Diseases and Sciences 6/2012

01.06.2012 | Original Article

Clinicopathologic Characteristics and Long-Term Prognosis of Scirrhous Hepatocellular Carcinoma

verfasst von: Jin Hee Lee, Moon Seok Choi, Geum Yeon Gwak, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Dongil Choi, Cheol Keun Park

Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Clinicopathologic features and long-term outcomes in patients with scirrhous hepatocellular carcinoma (S-HCC) are not fully defined.

Methods

We compared data of 37 patients with S-HCC and 604 with usual HCC (U-HCC) undergoing surgery.

Results

The S-HCC group showed less HBV infection (78.4 vs. 92.0%, P = 0.02), low serum AFP level (2320 ± 6356 vs. 3297 ± 18690 ng/ml, P < 0.0001), less delayed washout during CT (72.7 vs. 90.7%, P = 0.004), and low usefulness of clinical diagnostic criteria (32.4 vs. 57.5%, P = 0.003), compared to the U-HCC group. More portal vein invasion (18.9 vs. 4.1%, P = 0.03) and less liver cirrhosis (35.1 vs. 65.1%, P = 0.001) and fibrous capsule (40.5 vs. 81.6%, P < 0.001) were noted in the S-HCC group than the U-HCC group. Long-term survival rates were similar between the S-HCC and U-HCC groups, even with subgroup analysis according to Child-Pugh score and modified UICC stage.

Conclusion

The S-HCC group showed distinct patient and tumor characteristics but similar long-term outcome.
Literatur
1.
Zurück zum Zitat Matsuura S, Aishima S, Taguchi K, et al. ‘Scirrhous’ type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1. Histopathology. 2005;47:382–390.PubMedCrossRef Matsuura S, Aishima S, Taguchi K, et al. ‘Scirrhous’ type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1. Histopathology. 2005;47:382–390.PubMedCrossRef
2.
Zurück zum Zitat Kurogi M, Nakashima O, Miyaaki H, Fujimoto M, Kojiro M. Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;21:1470–1477.PubMed Kurogi M, Nakashima O, Miyaaki H, Fujimoto M, Kojiro M. Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;21:1470–1477.PubMed
3.
Zurück zum Zitat Ishak KG, Goodman Z, Stocker JT. Hepatocellular carcinoma. In: Rosai J, Sobin LH, eds. Tumors of the Liver and Intrahepatic Bile Duct. 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 1999:199–230. Ishak KG, Goodman Z, Stocker JT. Hepatocellular carcinoma. In: Rosai J, Sobin LH, eds. Tumors of the Liver and Intrahepatic Bile Duct. 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 1999:199–230.
4.
Zurück zum Zitat Iha H. Clinicopathological study on scirrhous hepatocellular carcinoma. A study of 12 resected cases. Acta Hepatol Jpn. 1994;28:855–863.CrossRef Iha H. Clinicopathological study on scirrhous hepatocellular carcinoma. A study of 12 resected cases. Acta Hepatol Jpn. 1994;28:855–863.CrossRef
5.
Zurück zum Zitat Japan LCSGO. Survey and Follow-Up Study of Primary Liver Cancer in Japan. Report 15. Kyoto: Liver Cancer Study group of Japan; 2002. Japan LCSGO. Survey and Follow-Up Study of Primary Liver Cancer in Japan. Report 15. Kyoto: Liver Cancer Study group of Japan; 2002.
6.
Zurück zum Zitat Kim SH, Lee WJ, Lim HK, Park CK. Sclerosing hepatic carcinoma: helical CT features. Abdom Imaging. 2007;32:725–729.CrossRef Kim SH, Lee WJ, Lim HK, Park CK. Sclerosing hepatic carcinoma: helical CT features. Abdom Imaging. 2007;32:725–729.CrossRef
7.
Zurück zum Zitat Goshima S, Kanematsu M, Yamada T, et al. Small scirrhous hepatocellular carcinoma with central scar: MR imaging findings. J Magn Reson Imaging. 2002;16:741–745.PubMedCrossRef Goshima S, Kanematsu M, Yamada T, et al. Small scirrhous hepatocellular carcinoma with central scar: MR imaging findings. J Magn Reson Imaging. 2002;16:741–745.PubMedCrossRef
8.
Zurück zum Zitat Yamashita Y, Fan ZM, Yamamoto H, et al. Sclerosing hepatocellular carcinoma: radiologic findings. Abdom Imaging. 1993;18:347–351.PubMedCrossRef Yamashita Y, Fan ZM, Yamamoto H, et al. Sclerosing hepatocellular carcinoma: radiologic findings. Abdom Imaging. 1993;18:347–351.PubMedCrossRef
9.
Zurück zum Zitat Yoshida J, Takayama T, Yamamoto H. Computed tomography of sclerosing hepatocellular carcinoma. Comput Med Imaging Graph. 1992;16:125–130.PubMedCrossRef Yoshida J, Takayama T, Yamamoto H. Computed tomography of sclerosing hepatocellular carcinoma. Comput Med Imaging Graph. 1992;16:125–130.PubMedCrossRef
10.
Zurück zum Zitat Kim SR, Imoto S, Nakajima T, et al. Scirrhous hepatocellular carcinoma displaying atypical findings on imaging studies. World J Gastroenterol. 2009;15:2296–2299.PubMedCrossRef Kim SR, Imoto S, Nakajima T, et al. Scirrhous hepatocellular carcinoma displaying atypical findings on imaging studies. World J Gastroenterol. 2009;15:2296–2299.PubMedCrossRef
11.
Zurück zum Zitat Kim SH, Lim HK, Lee WJ, Choi D, Park CK. Scirrhous hepatocellular carcinoma: comparison with usual hepatocellular carcinoma based on CT-pathologic features and long-term results after curative resection. Eur J Radiol. 2009;69:123–130.PubMedCrossRef Kim SH, Lim HK, Lee WJ, Choi D, Park CK. Scirrhous hepatocellular carcinoma: comparison with usual hepatocellular carcinoma based on CT-pathologic features and long-term results after curative resection. Eur J Radiol. 2009;69:123–130.PubMedCrossRef
12.
Zurück zum Zitat Sugiki T, Yamamoto M, Taka K, Nakano M. Specific characteristics of scirrhous hepatocellular carcinoma. Hepatogastroenterology. 2009;56:1086–1089.PubMed Sugiki T, Yamamoto M, Taka K, Nakano M. Specific characteristics of scirrhous hepatocellular carcinoma. Hepatogastroenterology. 2009;56:1086–1089.PubMed
13.
Zurück zum Zitat Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–430.PubMedCrossRef Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–430.PubMedCrossRef
14.
Zurück zum Zitat Bruis J, Sherman M. AASLD practice guideline: management of hepatocellular carcinoma. Hepatology. 2005;42:1209–1235. Bruis J, Sherman M. AASLD practice guideline: management of hepatocellular carcinoma. Hepatology. 2005;42:1209–1235.
15.
Zurück zum Zitat International Union Against Cancer (UICC). In: Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumors. 5th ed. New York. Wiley-Liss; 1997. International Union Against Cancer (UICC). In: Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumors. 5th ed. New York. Wiley-Liss; 1997.
16.
Zurück zum Zitat Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores—where are we and where should we go? J Hepatol. 2004;41:344–350.PubMedCrossRef Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores—where are we and where should we go? J Hepatol. 2004;41:344–350.PubMedCrossRef
17.
Zurück zum Zitat Okamura N, Yoshida M, Shibuya A, Sugiura H, Okayasu I, Ohbu M. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Pathol Int. 2005;55:724–731.PubMedCrossRef Okamura N, Yoshida M, Shibuya A, Sugiura H, Okayasu I, Ohbu M. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Pathol Int. 2005;55:724–731.PubMedCrossRef
18.
Zurück zum Zitat Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol. 2002;26:978–988.PubMedCrossRef Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol. 2002;26:978–988.PubMedCrossRef
19.
Zurück zum Zitat Yeh CN, Hung CF, Lee KF, Chen MF. Sclerosing hepatocellular carcinoma: clinicopathologic features in seven patients from Taiwan and review of the literature. Hepatogastroenterology. 2005;52:1201–1205.PubMed Yeh CN, Hung CF, Lee KF, Chen MF. Sclerosing hepatocellular carcinoma: clinicopathologic features in seven patients from Taiwan and review of the literature. Hepatogastroenterology. 2005;52:1201–1205.PubMed
20.
Zurück zum Zitat Kim BS, Lee SG, Hwang S, et al. Surgical treatment of sclerosing hepatocellular carcinoma. Korean J Hepatol. 2006;12:412–419.PubMed Kim BS, Lee SG, Hwang S, et al. Surgical treatment of sclerosing hepatocellular carcinoma. Korean J Hepatol. 2006;12:412–419.PubMed
21.
Zurück zum Zitat Ikai I, Itai Y, Okita K, et al. Report of the 15th follow-up survey of primary liver cancer. Hepatol Res. 2004;28:21–29.PubMedCrossRef Ikai I, Itai Y, Okita K, et al. Report of the 15th follow-up survey of primary liver cancer. Hepatol Res. 2004;28:21–29.PubMedCrossRef
22.
Zurück zum Zitat Asayama Y, Yoshimitsu K, Irie H, et al. Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology. 2006;238:150–155.PubMedCrossRef Asayama Y, Yoshimitsu K, Irie H, et al. Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology. 2006;238:150–155.PubMedCrossRef
23.
Zurück zum Zitat Valls C, Guma A, Puig I, et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging. 2000;25:490–496.PubMedCrossRef Valls C, Guma A, Puig I, et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging. 2000;25:490–496.PubMedCrossRef
24.
Zurück zum Zitat Yoshikawa J, Matsui O, Kadoya M, Gabata T, Arai K, Takashima T. Delayed enhancement of fibrotic areas in hepatic masses: CT-pathologic correlation. J Comput Assist Tomogr. 1992;16:206–211.PubMedCrossRef Yoshikawa J, Matsui O, Kadoya M, Gabata T, Arai K, Takashima T. Delayed enhancement of fibrotic areas in hepatic masses: CT-pathologic correlation. J Comput Assist Tomogr. 1992;16:206–211.PubMedCrossRef
25.
Zurück zum Zitat Jeon TY, Kim SH, Lee WJ, Lim HK. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma. Abdom Imaging. 2010;35:337–345.PubMedCrossRef Jeon TY, Kim SH, Lee WJ, Lim HK. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma. Abdom Imaging. 2010;35:337–345.PubMedCrossRef
26.
Zurück zum Zitat Yamashita Y, Fan ZM, Yamamoto H, et al. Spin-echo and dynamic gadolinium-enhanced FLASH MR imaging of hepatocellular carcinoma: correlation with histopathologic findings. J Magn Reson Imaging. 1994;4:83–90.PubMedCrossRef Yamashita Y, Fan ZM, Yamamoto H, et al. Spin-echo and dynamic gadolinium-enhanced FLASH MR imaging of hepatocellular carcinoma: correlation with histopathologic findings. J Magn Reson Imaging. 1994;4:83–90.PubMedCrossRef
27.
Zurück zum Zitat Troeger JS, Schwabe RF. Hypoxia and hypoxia-inducible factor 1alpha: potential links between angiogenesis and fibrogenesis in hepatic stellate cells. Liver Int. 2011;31:143–145.PubMedCrossRef Troeger JS, Schwabe RF. Hypoxia and hypoxia-inducible factor 1alpha: potential links between angiogenesis and fibrogenesis in hepatic stellate cells. Liver Int. 2011;31:143–145.PubMedCrossRef
28.
Zurück zum Zitat Copple BL, Bai S, Burgoon LD, Moon JO. Hypoxia-inducible factor-1alpha regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int. 2011;31:230–244.PubMedCrossRef Copple BL, Bai S, Burgoon LD, Moon JO. Hypoxia-inducible factor-1alpha regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int. 2011;31:230–244.PubMedCrossRef
Metadaten
Titel
Clinicopathologic Characteristics and Long-Term Prognosis of Scirrhous Hepatocellular Carcinoma
verfasst von
Jin Hee Lee
Moon Seok Choi
Geum Yeon Gwak
Joon Hyeok Lee
Kwang Cheol Koh
Seung Woon Paik
Byung Chul Yoo
Dongil Choi
Cheol Keun Park
Publikationsdatum
01.06.2012
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 6/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2075-x

Weitere Artikel der Ausgabe 6/2012

Digestive Diseases and Sciences 6/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.